Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors

Trial Profile

A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Crizotinib (Primary)
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Jun 2019 Planned End Date changed from 31 Jul 2018 to 30 Aug 2019.
    • 06 Jun 2017 Results (n=37; as of Aug 5, 2016), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top